

DAFTAR ISI

| | |
|---|--------------|
| PRASYARAT GELAR | <i>iii</i> |
| LEMBAR PENGESAHAN | <i>iv</i> |
| PENETAPAN PANITIA PENGUJI | <i>v</i> |
| UCAPAN TERIMA KASIH | <i>vi</i> |
| RINGKASAN | <i>xii</i> |
| SUMMARY | <i>xv</i> |
| ABSTRACT | <i>xviii</i> |
| DAFTAR TABEL | <i>xxiii</i> |
| DAFTAR GAMBAR | <i>xxiv</i> |
| DAFTAR SINGKATAN | <i>xxv</i> |
| CHAPTER I | <i>1</i> |
| INTRODUCTION | <i>1</i> |
| CHAPTER II | <i>18</i> |
| MATERNAL AND PERINATAL OUTCOME RELATED TO SEVERITY OF CHRONIC HYPERTENSION IN PREGNANCY | <i>18</i> |
| ABSTRACT | <i>18</i> |
| INTRODUCTION | <i>21</i> |
| MATERIAL AND METHODS | <i>21</i> |
| RESULTS | <i>23</i> |
| DISCUSSION | <i>34</i> |
| CONFLICT OF INTEREST | <i>38</i> |
| FUNDING | <i>38</i> |
| ACKNOWLEDGEMENTS | <i>39</i> |
| REFERENCE | <i>39</i> |
| CHAPTER III | <i>44</i> |
| SERUM HEME OXYGENASE 1 (HO-1), SOLUBLE FMS LIKE TYROSINE KINASE (sFlt-1) LEVEL, AND NEONATAL OUTCOME IN EARLY ONSET, LATE ONSET PREECLAMPSIA, AND NORMAL PREGNANCY | <i>44</i> |
| ABSTRACT | <i>44</i> |
| INTRODUCTION | <i>47</i> |
| MATERIAL AND METHODS | <i>49</i> |
| Study population..... | <i>50</i> |
| Blood samples and assays | <i>51</i> |
| RESULT | <i>51</i> |
| Clinical Characteristics and Risk Factors..... | <i>51</i> |
| Maternal Serum Heme Oxygenase-1 and sFlt-1 Level | <i>52</i> |
| Neonatal Outcome..... | <i>54</i> |
| DISCUSSION | <i>56</i> |

| | |
|---|------------|
| CONCLUSION | 58 |
| DECLARATION OF INTEREST | 59 |
| REFERENCES..... | 59 |
| CHAPTER IV..... | 63 |
| <i>CLINICAL CHARACTERISTICS OF ACUTE FATTY LIVER OF PREGNANCY IN A TERTIARY INDONESIAN HOSPITAL.....</i> | 63 |
| ABSTRACT..... | 63 |
| INTRODUCTION..... | 66 |
| MATERIAL AND METHODS..... | 67 |
| RESULT | 68 |
| General Characteristics of AFLP Patients..... | 68 |
| Clinical Manifestation of AFLP Patients..... | 69 |
| Laboratory Results in AFLP Patients..... | 69 |
| Management of AFLP Patients | 70 |
| Maternal and Fetal Outcome of AFLP Patients | 71 |
| Maternal Death Risk Factors in AFLP Patients | 73 |
| Risk Factors of IUFD | 76 |
| DISCUSSION..... | 77 |
| General Characteristics of AFLP Patients..... | 77 |
| Clinical Manifestation of AFLP Patients | 77 |
| Laboratory Results in AFLP Patients..... | 78 |
| Management of AFLP Patients | 78 |
| Maternal and Fetal Outcome of AFLP Patients | 79 |
| CONCLUSION | 80 |
| DISCLOSURE OF INTEREST | 81 |
| REFERENCE | 81 |
| CHAPTER V..... | 83 |
| <i>GENERAL DISCUSSIONS</i> | 83 |
| CHAPTER 2..... | 83 |
| Recommendation From The Study..... | 87 |
| CHAPTER 3..... | 88 |
| Recommendation From The Study..... | 92 |
| CHAPTER 4..... | 93 |
| Recommendation From The Study..... | 99 |
| THE DEVELOPMENT OF NEW CONCEPT | 100 |
| CHAPTER VI..... | 109 |
| CONCLUSSION | 109 |
| <i>PHD/ DOCTORAL PORTFOLIO.....</i> | 112 |
| 1. IDENTITY..... | 112 |
| 2. TEACHING ACTIVITY | 113 |
| 3. PUBLICATIONS | 114 |
| 4. SEMINAR, WORKSHOP & CONFERENCE | 120 |

| | |
|---|------------|
| 5. TRAINING | 122 |
| 6. OTHER POSITION & ACTIVITIES | 122 |

DAFTAR TABEL**Chapter 2**

| | |
|--|----|
| Table 1. Number of Chronic Hypertension in Pregnancy Cases 2013-2017 | 22 |
| Table 2. Antenatal Care (ANC) Characteristics | 23 |
| Table 3. Maternal Characteristics of Patients with Chronic Hypertension in Pregnancy | 24 |
| Table 4. Maternal Outcome in Chronic Hypertension Patients | 28 |
| Table 5. Perinatal Outcome in Chronic Hypertension Patients | 30 |
| Table 6. Logistic Regression of Model Risk Factor for Stage 2 Chronic Hypertension | 31 |

Chapter 3

| | |
|--|----|
| Table 1. Characteristics and Risk Factors in Early Onset Preeclampsia, Late Onset Preeclampsia, and Control Groups | 50 |
| Table 2. Maternal serum level of HO, sFlt1 and Neonatal Outcome in Early Onset Preeclampsia, Late Onset Preeclampsia, and Control Groups | 51 |
| Table 3. Correlation between Maternal serum level of HO, sFlt-1 and Neonatal Outcome | 54 |

Chapter 4

| | |
|---|----|
| Table 1. General Maternal Characteristics of AFLP patients | 67 |
| Table 2. Maternal and Fetal Outcome of AFLP Patient | 70 |
| Table 3. Maternal Death Versus Survivor and IUFD Versus life birth in 18 Indonesian AFLP Patients | 72 |
| Table 4. Comparison of Laboratory Test Results of Maternal death and surviving AFLP Patients, and IUFD - life birth babies. | 74 |

DAFTAR GAMBAR

Chapter 3

Figure 1. Plot Distribution of maternal serum HO level in Early Onset PE, Late Onset PE, and Control Groups, based on gestational age 52

Figure 2. Plot Distribution of maternal serum sFlt-1 level in Early Onset PE, Late Onset PE, and Control Groups, based on gestational age 53

Chapter 4

Figure 1. Methods and Location of Labor of AFLP patients 69

Chapter 5

Figure 1. Hypothesis illustrating the possible role of fetal and maternal MTP mutations in developing AFLP 93

Figure 2. The new concepts of relation between chronic hypertension, superimposed preeclampsia, early onset preeclampsia, late onset preeclampsia, serum sFlt-1, serum HO-1, and HELLP syndrome as the imitators of preeclampsia. 101

DAFTAR SINGKATAN

| | |
|-------|--|
| AFLP | : Acute Fatty Liver of Pregnancy |
| AKI | : Acute Kidney Injury |
| ALT | : Amino Alanine Transferase |
| ANC | : Antenatal Care |
| AS | : Apgar score |
| AST | : Aspartate Amino Transferase |
| BMI | : Body Mass Index |
| BUN | : Blood Urine Nitrogen |
| CC | : Coefficient Correlation |
| CFR | : Case Fatality Rate |
| CH | : Chronic Hypertension |
| CHIPS | : Control of Hypertension in Pregnancy Study |
| CI | : Confidence Interval |
| CO | : Carbon Monoxide |
| CVA | : Cerebro Vascular Accident |
| DIC | : Disseminated Intravascular Coagulation |
| DMPA | : Depomedroxyprogesterone Acetate |
| ELISA | : Enzyme-linked Immunosorbent Assay |
| EO-PE | : Early Onset Preeclampsia |
| HELLP | : Hemolysis, Elevated Liver Enzyme, and Low Platelet Count syndrome |

| | |
|--------|--|
| HICs | : High Income Countries |
| HO | : Heme Oxygenase |
| ICU | : Intensive Care Unit |
| ISSHP | : International Society for The Study of Hypertension in Pregnancy |
| IUD | : Intrauterine Device |
| IUGR | : Intrauterine Growth Restriction |
| IUFD | : Intrauterine Fetal Death |
| JNC 7 | : The Seventh Joint National Committee |
| LCHAD | : Long Chain 3-Hydroxyacyl coenzyme A-Dehydrogenase |
| LDH | : Lactate Dehydrogenase |
| LMICs | : Low-middle Income Countries |
| LO-PE | : Late Onset Preeclampsia |
| MPA | : Medroxyprogesterone Acetate |
| mRNA | : Messenger Ribo Nucleic Acid |
| MRI | : Magnetic Resonance Imaging |
| MTP | : Mitochondrial Trifunctional Protein |
| NICU | : Neonatal Intensive Care Unit |
| NP | : Normal Pregnancy |
| OCC | : Oral Combination Contraceptive |
| OR | : Odd Ratio |
| PE | : Preeclampsia |
| PIGF | : Placental Growth Factor |
| PPCM | : Peripartum Cardiomiopathy |
| PT | : Prothrombin Time |
| VEGF-A | : Vascular Endothelial Growth Factor-A |

| | |
|--------|--|
| RR | : Relative Risk |
| sEng | : Soluble Endoglin |
| SD | : Standard Deviation |
| sFlt-1 | : Soluble FMS like Tyrosine Kinase 1 |
| SK | : Serum Creatinine |
| SKDI | : Survei Demografi dan Kesehatan Indonesia |
| SLE | : Systemic Lupus Erythematosus |
| UK | : United Kingdom |
| uNK | : Uterine Natural Killer |
| US | : United States |
| WHO | : World Health Organization |